Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
Lepu Biopharma gets taste of spring with first revenues
The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: Lepu Biopharma began to sell its first product last…